Phase 2 N=45 Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Carcinoid Tumors
Primary: Symptom Control (Diarrhea/Flushing) Using a Patient Symptom Diary — 3; 9; 32 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=19 Cabozantinib and Nivolumab for Carcinoid Tumors
Carcinoid Tumor · Carcinoid Tumor of GI System · Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 0 percentage of participants
Phase 3 N=85 Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
Neuroendocrine Tumors
Primary: Time to Tumor Progression Documented by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) — 14.3; 6.0 Months
Phase 2 N=20 Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Carcinoid Tumors · Pancreatic NET
Primary: Overall Radiographic Response Rate (ORR) — 0 Participants
Phase 2 N=43 A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Carcinoid Tumors
Primary: Progression-Free Survival (PFS) — 14.2 months
Phase 2 N=19 Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
Carcinoid Tumor
Primary: Progression Free Survival — 11.8 months
Phase 2 N=60 AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Neuroendocrine Tumor · Carcinoid Tumor · Pancreatic Neuroendocrine Tumor
Primary: Objective Response Rate — 0.0 percentage of patients
N/A N=399 Nutrition in Gastroenteropancreatic Neuroendocrine Tumor
Gastroenteropancreatic Neuroendocrine Tumor
Primary: Prevalence of Malnutrition in GEP NET — 247; 152 Participants
Phase 3 N=76 Telotristat Etiprate for Carcinoid Syndrome Therapy
Carcinoid Syndrome
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Double-Blind Treatment Period — 21; 25; 22 Participants
Phase 3 N=124 Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Carcinoid Syndrome
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 22; 100 Participants
Phase 2 N=341 Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
Neuroendocrine Tumors · Von Hippel-Lindau Syndrome · Hippel-Lindau Disease
Primary: Number of Lesions Detected Using the 68Gallium-DOTATATE Positron Emission Tomography (PET/Computed Tomography (CT)) Scan — 847 Number of lesions
Phase 2 N=30 A Study of Axitinib in Advanced Carcinoid Tumors
Carcinoid Tumor
Primary: Rate of Progression Free Survival (PFS) — 74.5 percentage of participants
N/A N=24 Current Management of Gastrointestinal Stromal Tumors (GIST) in the Region of Coquimbo
Gastrointestinal Stromal Tumors
Primary: Number of Patients Who Survived — 5 Participants
Phase 2 N=44 Pazopanib as Single Agent in Advanced NETs
Advanced/Metastatic Neuroendocrine Tumors
Primary: Clinical Benefit Rate — 11 Participants
Phase 3 N=429 Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
Carcinoid Tumor · Malignant Carcinoid Syndrome
Primary: Progression Free Survival (PFS) as Per Adjudicated Central Radiology Review — 16.43; 11.33 Months
Phase 2 N=3 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
Gastrinoma · Glucagonoma · Insulinoma
Primary: PFS
Phase 2 N=40 Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors
Neuroendocrine Tumors
Primary: 12-month Progression Free Survival (PFS) — 64.7 percentage of participants w/ 12 mo PFS
Phase 3 N=231 A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Carcinoid Tumor of the Small Bowel · Neuroendocrine Tumour
Primary: Progression Free Survival (PFS) — NA; 8.5 months — p=<0.0001
Phase 2 N=18 A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers
Neuroendocrine Tumors
Primary: Number of Participants With Improved, Stable, or Worsened Change In Chromogranin A (CgA) Biomarker Levels From Baseline — 1; 11; 6 Participants
Phase 2 N=46 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Gastrointestinal Carcinoid Tumor · Islet Cell Tumor · Neoplastic Syndrome
Primary: Four-month Progression-free Survival Rate — 78.5 percentage of participants — p=<0.001
Phase 2 N=116 Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
Well-differentiated Non-functional NET of Thoracic Origin · Well-differentiated Non-functional NET of Gastrointestinal Origin · Well-differentiated Non-functional NET of Pancreatic Origin
Primary: Overall Response Rate (ORR) by RECIST 1.1 and as Per Blinded Independent Central Review (BIRC). — 7.4; 4.8 Percentage of participants
Phase 2 N=123 Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
Phase 3 N=256 Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Neuroendocrine Tumors · Advanced Cancer
Primary: Efficacy of Axitinib in Terms of PFS (Investigator Assessment) — 17.2; 13.1 months — p=0.324
Phase 2 N=15 Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
Carcinoid Syndrome
Primary: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Drug-Related TEAEs in the Core Phase — 15; 5 Participants
Phase 2 N=122 Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
Neuroendocrine Tumors · Carcinoid Tumors · Neuroblastoma
Primary: Number of Participants With a Change in Treatment Management Based on Findings of the Gallium Ga 68-edotreotide PET/CT Scan — 54; 6; 54 Participants
Phase 2 N=83 A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.
Neoplasms
Primary: Progression-Free Survival (PFS) - Percentage of Participants With an Event — 52.9; 53.1 percentage of participants
Phase 2 N=39 Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma
Neuroendocrine Carcinoma
Primary: Net Change Relative to Baseline in Tumor Blood Flow — -0.44; -0.12; -0.60; -0.40 ml/min/100gm
Phase 2 N=36 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
Metastatic Gastrointestinal Carcinoid Tumor · Pulmonary Carcinoid Tumor · Recurrent Gastrointestinal Carcinoid Tumor
Primary: Objective Tumor Response Rate (Defined as Partial or Complete Response as Defined by the RECIST Criteria) — 2 participants
Phase 2 N=64 Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis
Peritoneal Neoplasms · Intestinal Obstruction · Carcinomatosis
Primary: Number of Participants With Treatment Success From Day 10 to Day 13 — 12; 9; 19; 13 Participants
Phase 2 N=61 Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Carcinoid Tumor · Pancreatic Neuroendocrine Tumor
Primary: Objective Response Rate (ORR) — 3; 7 Participants